Report cover image

Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146938

Description

Human papillomavirus-positive oropharyngeal cancer is a type of head and neck cancer caused by HPV infection, primarily affecting the throat, base of the tongue, and tonsils. The disease accounts for a significant proportion of oropharyngeal cancers globally, with India’s HPV-related cancer cases projected to rise to 121,302 by 2025. There is a high unmet clinical need for better therapies as current options, such as surgery, radiation, and chemotherapy, have limitations. A growing focus on immunotherapy and targeted treatments is expected to drive advancements in the drug pipeline, offering hope for improved patient outcomes and a higher quality of life.

Report Coverage

The Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into human papillomavirus-positive oropharyngeal cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human papillomavirus-positive oropharyngeal cancer. The human papillomavirus-positive oropharyngeal cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The human papillomavirus-positive oropharyngeal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with human papillomavirus-positive oropharyngeal cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to human papillomavirus-positive oropharyngeal cancer.

Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Outlook

Human papillomavirus-positive oropharyngeal cancer is a subset of head and neck cancers caused by persistent infection with high-risk HPV strains, primarily HPV-16. It develops in the oropharynx, including the tonsils and base of the tongue, due to viral integration into host cells, leading to uncontrolled cell growth. The disease is more prevalent in younger, non-smoking individuals and is linked to changing lifestyle factors and sexual behavior.

Human papillomavirus-positive oropharyngeal cancer is treated using surgery, radiation therapy, and chemotherapy. However, these approaches often result in significant side effects and limited long-term effectiveness. Emerging therapies, such as immunotherapy and precision-targeted drugs, aim to improve survival rates while reducing toxicity. Ongoing clinical trials are focused on developing novel treatment modalities, including HPV-targeted vaccines and combination therapies, to address the high unmet medical need in managing this condition.

Human Papillomavirus-Positive Oropharyngeal Cancer Epidemiology

Human papillomavirus-positive oropharyngeal cancer is increasingly prevalent globally, with 29,000 new cases annually, accounting for 30% of total oropharyngeal cancer cases. In India, HPV-related cancers are projected to reach 121,302 by 2025, with oropharyngeal cancer representing 63.2% of HPV-related cancers. Regions like North America and Northern Europe have seen rising HPV+ oropharyngeal cancer cases, driven by decreased smoking and changing sexual behaviors, emphasizing the need for vaccination and screening initiatives.

Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of human papillomavirus-positive oropharyngeal cancer drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Gene Therapies
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
Human Papillomavirus-Positive Oropharyngeal Cancer – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total human papillomavirus-positive oropharyngeal cancer clinical trials.

Human Papillomavirus-Positive Oropharyngeal Cancer – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the human papillomavirus-positive oropharyngeal cancer pipeline analysis include small molecules, gene therapies, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus-positive oropharyngeal cancer.

Human Papillomavirus-Positive Oropharyngeal Cancer Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR human papillomavirus-positive oropharyngeal cancer report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Human Papillomavirus-Positive Oropharyngeal Cancer clinical trials:
  • Nykode Therapeutics ASA
  • Merck Sharp & Dohme LLC
  • Agenus Inc.
  • AstraZeneca
  • Cue Biopharma
  • PDS Biotechnology Corp.
  • TScan Therapeutics, Inc.
Human Papillomavirus-Positive Oropharyngeal Cancer Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for human papillomavirus-positive oropharyngeal cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of human papillomavirus-positive oropharyngeal cancer drug candidates.

Biological: 9 valent human papillomavirus vaccine

The Phase III trial, sponsored by Weill Medical College of Cornell University, examines the efficacy of the nine-valent HPV vaccine's efficacy in preventing persistent oral HPV infection in men living with HIV. The study involves 700 participants and is expected to be completed by April 2026. This randomized, double-blinded trial aims to address HPV-associated oropharyngeal cancer risks.

Drug: Balstilimab

The M.D. Anderson Cancer Center is conducting a Phase 2 study investigating Balstilimab (AGEN2034) for its ability to clear HPV in plasma cfDNA of HPV-positive oropharyngeal cancer patients after definitive therapy. This interventional study, with an estimated 20 participants, focuses on viral clearance and long-term outcomes. The study is anticipated to be completed by February 15, 2028 and promises advancements in immunotherapy.

Reasons To Buy This Report

The Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus-positive oropharyngeal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within human papillomavirus-positive oropharyngeal cancer pipeline insights.

Key Questions Answered in the Human Papillomavirus-Positive Oropharyngeal Cancer – Pipeline Insight Report
  • What is the current landscape of human papillomavirus-positive oropharyngeal cancer pipeline drugs?
  • Which companies/institutions are developing human papillomavirus-positive oropharyngeal cancer emerging drugs?
  • How many phase II drugs are currently present in the human papillomavirus-positive oropharyngeal cancer pipeline drugs?
  • Which company is leading the human papillomavirus-positive oropharyngeal cancer pipeline development activities?
  • What is the current human papillomavirus-positive oropharyngeal cancer therapeutic assessment?
  • What are the opportunities and challenges present in the human papillomavirus-positive oropharyngeal cancer drug pipeline landscape?
  • What is the efficacy and safety profile of human papillomavirus-positive oropharyngeal cancer pipeline drugs?
  • Which companies/institutions are involved in human papillomavirus-positive oropharyngeal cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in human papillomavirus-positive oropharyngeal cancer?
Related Reports

Global Human Papillomavirus (HPV) Vaccine Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Human Papillomavirus-Positive Oropharyngeal Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Human Papillomavirus-Positive Oropharyngeal Cancer
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Human Papillomavirus-Positive Oropharyngeal Cancer: Epidemiology Snapshot
5.1 Human Papillomavirus-Positive Oropharyngeal Cancer Incidence by Key Markets
5.2 Human Papillomavirus-Positive Oropharyngeal Cancer – Patients Seeking Treatment in Key Markets
6 Human Papillomavirus-Positive Oropharyngeal Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Human Papillomavirus-Positive Oropharyngeal Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Human Papillomavirus-Positive Oropharyngeal Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Human Papillomavirus-Positive Oropharyngeal Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Biological: 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Balstilimab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: CUE-101, Keytruda, Pembrolizumab
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Human Papillomavirus-Positive Oropharyngeal Cancer, Key Drug Pipeline Companies
14.1 Nykode Therapeutics ASA
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Merck Sharp & Dohme LLC
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Agenus Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 AstraZeneca
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Cue Biopharma
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 PDS Biotechnology Corp.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 TScan Therapeutics, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us